AU2015254665A1 - Treatment and prevention of alzheimer's disease (AD) - Google Patents

Treatment and prevention of alzheimer's disease (AD) Download PDF

Info

Publication number
AU2015254665A1
AU2015254665A1 AU2015254665A AU2015254665A AU2015254665A1 AU 2015254665 A1 AU2015254665 A1 AU 2015254665A1 AU 2015254665 A AU2015254665 A AU 2015254665A AU 2015254665 A AU2015254665 A AU 2015254665A AU 2015254665 A1 AU2015254665 A1 AU 2015254665A1
Authority
AU
Australia
Prior art keywords
aluminium
aluminium salt
oxyhydroxide
patient
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015254665A
Other languages
English (en)
Inventor
Markus Mandler
Frank Mattner
Walter Schmidt
Achim Schneeberger
Arne Von Bonin
Wolfgang Zauner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affiris AG
Original Assignee
Affiris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris AG filed Critical Affiris AG
Publication of AU2015254665A1 publication Critical patent/AU2015254665A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2015254665A 2014-04-29 2015-04-29 Treatment and prevention of alzheimer's disease (AD) Abandoned AU2015254665A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14166388.0 2014-04-29
EP14166355.9 2014-04-29
EP14166388 2014-04-29
EP14166355 2014-04-29
PCT/EP2015/059341 WO2015165968A1 (en) 2014-04-29 2015-04-29 Treatment and prevention of alzheimer's disease (ad)

Publications (1)

Publication Number Publication Date
AU2015254665A1 true AU2015254665A1 (en) 2016-11-10

Family

ID=53039897

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015254665A Abandoned AU2015254665A1 (en) 2014-04-29 2015-04-29 Treatment and prevention of alzheimer's disease (AD)

Country Status (12)

Country Link
US (3) US11065273B2 (enExample)
EP (2) EP4209222A1 (enExample)
JP (1) JP2017515812A (enExample)
KR (1) KR102506460B1 (enExample)
CN (1) CN106659736A (enExample)
AU (1) AU2015254665A1 (enExample)
CA (1) CA2946931A1 (enExample)
DK (1) DK3137094T3 (enExample)
FI (1) FI3137094T3 (enExample)
PL (1) PL3137094T3 (enExample)
PT (1) PT3137094T (enExample)
WO (1) WO2015165968A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106535924A (zh) * 2014-04-29 2017-03-22 阿费里斯股份公司 阿尔茨海默病(ad)的治疗和预防
KR102506460B1 (ko) 2014-04-29 2023-03-03 어드밴티지 테라퓨틱스, 인코포레이티드 알츠하이머병（ａｄ）의 치료 및 예방
WO2015165966A1 (en) * 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016327A1 (en) 1993-01-14 1994-07-21 Pollard Harvey B Methods and compositions for blocking amyloid protein ion channels
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
NZ536064A (en) * 2002-04-19 2008-06-30 Univ Toronto Immunological methods and compositions for the treatment of alzheimer's disease
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
US10383887B2 (en) 2008-02-20 2019-08-20 New York University Preventing and treating amyloid-beta deposition by stimulation of innate immunity
AT506820B1 (de) 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
AT506819B1 (de) 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
EP2145898A1 (en) * 2008-07-15 2010-01-20 CHIESI FARMACEUTICI S.p.A. Anti-amyloid immunogenic compositions, methods and uses
CN104436212A (zh) 2010-03-29 2015-03-25 诺华股份有限公司 包含与病毒样颗粒偶联的淀粉样β1-6肽及佐剂的组合物
GB201101331D0 (en) 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
WO2015165966A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
CN106535924A (zh) 2014-04-29 2017-03-22 阿费里斯股份公司 阿尔茨海默病(ad)的治疗和预防
KR102506460B1 (ko) 2014-04-29 2023-03-03 어드밴티지 테라퓨틱스, 인코포레이티드 알츠하이머병（ａｄ）의 치료 및 예방

Also Published As

Publication number Publication date
FI3137094T3 (fi) 2023-03-20
KR102506460B1 (ko) 2023-03-03
JP2017515812A (ja) 2017-06-15
EP3137094B1 (en) 2022-12-07
EP3137094A1 (en) 2017-03-08
US11857568B2 (en) 2024-01-02
CN106659736A (zh) 2017-05-10
US11065273B2 (en) 2021-07-20
PT3137094T (pt) 2023-03-09
DK3137094T3 (da) 2023-02-27
US20220000908A1 (en) 2022-01-06
CA2946931A1 (en) 2015-11-05
WO2015165968A1 (en) 2015-11-05
EP4209222A1 (en) 2023-07-12
US20170049810A1 (en) 2017-02-23
KR20160145821A (ko) 2016-12-20
US20240148782A1 (en) 2024-05-09
PL3137094T3 (pl) 2023-03-13

Similar Documents

Publication Publication Date Title
US20240148782A1 (en) Treatment and prevention of alzheimer's disease (ad)
US20220062412A1 (en) Treatment of alzheimer's disease (ad) with an aluminum salt
EP3269376B1 (en) Treatment and prevention of alzheimer's disease (ad)
WO2015165971A1 (en) Treatment and prevention of alzheimer's disease (ad)

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted